Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL4162940 | 0.80 | ALDH1A1 (0.53) | POLBMAPTKDM4EALOX15HSD17B10 | |
| Propionic Acid SCHEMBL4155568 | 0.80 | PIM1 (0.41) | ALDH1A1 | |
| Propionic Acid SCHEMBL4160262 | 0.80 | GABRA1 (0.48) | CSF1RMAPTKDM4EGAAHSD17B10 | |
| Propionic Acid SCHEMBL4160296 | 0.79 | GRM5 (0.44) | MAPT | |
| SCHEMBL3250318 | 0.79 | MMP13 (0.45) | MMP13GRIN1ALKPOLBMAPT | |
| SCHEMBL4159597 | 0.78 | MMP13 (0.41) | MMP13GRIN1ALKPOLBMAPT | |
| Propionic Acid SCHEMBL4157681 | 0.77 | GAA (0.54) | EGFRPOLBMAPTKDM4EGAA | |
| Propionic Acid SCHEMBL4165408 | 0.77 | GABRA1 (0.39) | GRIN1POLBMAPTKDM4EHSD17B10 | |
| SCHEMBL3251726 | 0.77 | KDM4E (0.39) | MMP13GRIN1POLBKDM4EGAA | |
| Propionic Acid SCHEMBL4159519 | 0.74 | MET (0.34) | BRD4MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | MMP13 3517/4885BRD4 545/4885GRIN1 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.